Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 6, 2008, Pages 659-661

  Lin, Chia Chi ^a,b   Pu, Yeong Shiau ^a   Hsu, Chih Hung ^a,b   Keng, Hsiao Yi ^a,b   Cheng, Ann Lii ^a,b   Yang, Chih Hsin ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Arsenic; Carcinoma; Consciousness disorders; Transitional cell; Ureteral neoplasms

Indexed keywords

ARSENIC TRIOXIDE; ASADIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL; THIAMINE; UNCLASSIFIED DRUG;

ACUTE BRAIN DISEASE; ADULT; AGED; ARTICLE; BEHAVIOR CHANGE; CASE REPORT; CONFUSION; CONSCIOUSNESS DISORDER; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; HUMAN; HYPONATREMIA; LABORATORY TEST; LUMBAR PUNCTURE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROIMAGING; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOM; UROGENITAL TRACT CANCER; UROTHELIUM;

ACUTE DISEASE; AGED; ANTINEOPLASTIC AGENTS; ARSENICALS; BRAIN DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OXIDES; THIAMINE DEFICIENCY; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 55249123208     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.02.018     Document Type: Article

References (14)

1. Soignet S.L., Frankel S.R., Douer D., et al. United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia. J Clin Oncol 19 (2001) 3852-3860
2. Pu Y.-S., Yang S.-M., Huang Y.-K., et al. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol Appl Pharmacol 218 (2007) 99-106
3. Yang C.-H., Kuo M.-L., Chen J.-C., et al. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 81 (1999) 796-799
4. Pu Y.-S., Hour T.-C., Chen J., et al. Cytotoxicity of arsenic trioxide to transitional carcinoma cells. Urology 60 (2002) 346-350
5. Miller Jr. W.H., Schipper H.M., Lee J.S., et al. Mechanisms of action of arsenic trioxide. Cancer Res 62 (2002) 3893-3903
6. Pu Y.-S., Hour T.-C., Chen J., et al. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma-characterizing its apoptotic pathway. Anticancer Drugs 13 (2002) 293-300
7. Lin C.-C., Hsu C.-H., Huang C.-Y., et al. Phase II trial of weekly paclitaxel, cisplatin plus infusional high-dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma. J Urol 176 (2007) 84-89
8. Vuky J., Yu R., Schwartz L., et al. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 20 (2002) 327-330
9. Kim K.B., Bedikian A.Y., Camacho L.H., et al. A Phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 104 (2005) 1687-1692
10. Lin C.-C., Hsu C., Hsu C.-H., et al. Arsenic trioxide in patients with hepatocellular carcinoma: A Phase II trial. Invest New Drugs 25 (2007) 77-84
11. Camacho L.H., Hong D.S., Gutierrez C., et al. Organic arsenic in patients (pts) with advanced solid tumors: Phase-1 results of ZIO-101 (s-dimethylarsino-glutathione). J Clin Oncol 25 (2007) 3554 [Meeting Abstract]
12. Samikkannu T., Chen C.H., Yih L.H., et al. Reactive oxygen species are involved in arsenic trioxide inhibition of pyruvate dehydrogenase activity. Chem Res Toxicol 16 (2003) 409-414
13. Yip S.-F., Yeung Y.-M., and Tsui E.Y.-K. Severe neurotoxicity following arsenic therapy for acute promyelocytic leukemia: Potentiation by thiamine deficiency. Blood 99 (2002) 3481-3482
14. Santos N.A., Bezerra C.S., Martins N.M., et al. Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism, and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 61 (2008) 145-155